GlassScriptPhysician profile
Feba Geevarghese
NPI 1134671605
$9,150.09
in general payments reported to CMS, 2019-2025
35 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,865 · 2022: $1,984 · 2023: $1,478 · 2024: $2,240 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,300.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,701.42 | 2021-2025 | Relistor, Trulance |
| Scilex Pharmaceuticals INC. | $1,691.25 | 2021-2025 | Ztlido |
| Boston Scientific Corporation | $1,576.92 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept |
| Collegium Pharmaceutical, INC. | $956.13 | 2022-2025 | Xtampza, Belbuca |
| Abbott Laboratories | $626.56 | 2022-2025 | Proclaim, Eterna |
| Averitas Pharma INC. | $304.49 | 2025 | Qutenza |
| Protega Pharmaceutials INC | $226.85 | 2022-2023 | Roxybond |
| Nalu Medical, INC. | $187.47 | 2021-2024 | Nalu Neurostimulation System |
| Biodelivery Sciences International, INC. | $170.89 | 2021 | |
| Zimmer Biomet Holdings, INC. | $150.73 | 2023-2025 | Comprehensive, Gel-One Cross-Linked Hyaluronate |
| Alkermes, INC. | $139.70 | 2025 | Vivitrol |
| Valinor Pharma, LLC | $128.27 | 2023-2025 | Movantik |
| Arbor Pharmaceuticals, INC. | $105.57 | 2021-2022 | |
| Nevro Corp. | $103.23 | 2022-2024 | Senza |
| Azurity Pharmaceuticals, INC. | $99.95 | 2023-2025 | Horizant, Horizant |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $94.09 | 2022-2023 | Gralise |
| Grt US Holding, INC. | $84.33 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $75.49 | 2025 | |
| Vertos Medical, INC. | $72.61 | 2024 | Mild Device Kit |
| Forte Bio-Pharma LLC | $71.47 | 2021-2024 | Prolate, Nalocet |
| Teva Pharmaceuticals USA, INC. | $71.27 | 2021-2024 | Austedo Xr |
| Ibsa Pharma INC. | $70.35 | 2023-2024 | Tirosint, Licart, Tirosint |
| Amneal Pharmaceuticals LLC | $54.58 | 2022-2023 | Lyvispah |
| Foundation Fusion Solutions, LLC | $53.92 | 2024-2025 | |
| Redhill Biopharma INC. | $49.76 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.35 | 2022 | |
| Avanir Pharmaceuticals, INC. | $46.57 | 2021-2022 | |
| Globus Medical, INC. | $34.49 | 2025 | Senza |
| Biotronik Nro, INC. | $34.07 | 2025 | Prospera |
| Biogen, INC. | $25.53 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.49 | 2021 | |
| Sanofi Pasteur INC. | $21.30 | 2022 | |
| Amgen INC. | $17.30 | 2021 | |
| Pfizer INC. | $15.97 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feba Geevarghese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.